



Sequella, Incorporated
9610 Medical Center Drive
Suite 200
Rockville, MD 20850
Tele: 301-762-7776
Fax: 301-762-7778

NEWS RELEASE

FOR IMMEDIATE RELEASE

DR. CAROL NACY OF SEQUELLA, INC. NAMED AS ONE OF FAST COMPANY MAGAZINE'S FAST 50 CHAMPIONS OF INNOVATION

February 15, 2002 – Rockville, MD – Dr. Carol Nacy, Founder and CEO of Sequella, Inc., has been named as one of Fast Company magazine's "Fast 50" innovators – individuals whose achievements helped change their companies or society. Dr. Nacy's achievements were selected from more than 1,650 online submissions representing more than 30 countries.

Dr. Nacy was chosen as a Fast 50 Leader, a category that is described by Fast Company as "Senior Executives who create value through the power of their ideas, the authenticity of their character and the intensity of their commitment." Dr. Nacy's nominated entry, titled, "Set the Agenda" can be found at <http://www.fastcompany.com/fast50/people/leaders/06.html>.

According to Fast Company, Dr. Carol Nacy is "...a woman on a mission: Convince the world that tuberculosis (a disease with 8 million new active cases each year) is a priority public-health problem and develop vaccines, drugs, and diagnostics." Articulate and passionate, Dr. Nacy is an outstanding story of how one woman's vision and sheer determination may change the course of medical history in much the same way as the polio vaccine devised by Dr. Jonas Salk.

Dr. Nancy, a microbiologist turned entrepreneur, also founded the Sequella Global Tuberculosis Foundation to attack TB from both a commercial and nonprofit angle. The Sequella Foundation has received a \$25 million commitment from the Bill and Melinda Gates Foundation to assist researchers and the academic community in identifying and developing new concepts and tools to control the global TB epidemic. At the same time, under Dr. Nancy's leadership, Sequella, Inc. in only five years has identified and developed five TB products, including the world's first active TB diagnostic entering Phase III clinical trials in March of 2002 and a therapeutic vaccine entering Phase I clinical trials in mid-2002.

The Fast 50 were selected by a distinguished panel consisting of astronaut Sally Ride, management guru Tom Peters, noted futurist Watts Wacker, Kevin Roberts, CEO, Saatchi & Saatchi, Craig Conway, and Zoe Baird, President, Markle Foundation.

The Fast 50 will appear in the March issue of Fast Company, the nation's leading magazine for management innovators, hitting newsstands on February 19. Profiles of the Fast 50, as well as all reader submissions, may be accessed online at the special Fast 50 Website at www.fastcompany.com/fast50

About Fast Company Magazine

Founded in 1996 and published monthly, Boston-based *Fast Company* (www.fastcompany.com) covers ideas, trends and individuals devoted to managing change in today's economy. The magazine was acquired in 2000 by G+J USA, one of America's largest magazine publishers. Fast Company is part of the company's newly-formed Business Innovator Group.

About Sequella, Inc.

Sequella, Inc. is a biotechnology company dedicated to commercializing therapeutics, vaccines, and diagnostics that can alleviate the global burden of infectious disease. The company, headquartered in Rockville, MD, is focusing its initial research efforts on products to address the growing TB problem worldwide. For more information about Sequella, Inc., please visit www.sequella.com.

Contact:

Hope Vaughn
Columbia Strategy Group, Inc. for Sequella, Inc.
(212) 784-7524
hvaughn@columbiastrategy.com